Francesco Boin

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 58:1165-74. 2008
  2. ncbi Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
  3. ncbi Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients
    Francesco Boin
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 60:2480-9. 2009
  4. ncbi Scleroderma-like fibrosing disorders
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:199-220; ix. 2008
  5. ncbi Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    Elizabeth N Le
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:1104-7. 2011
  6. ncbi Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
    Thomas Grader-Beck
    Correspondence to Thomas Grader Beck, Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 4100, Mason Lord Center Tower, Baltimore, MD 21224, USA
    Ann Rheum Dis 70:2218-24. 2011
  7. ncbi Autoimmunity in systemic sclerosis: current concepts
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Bldg Center Tower, Suite 4100, Room 412, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 9:165-72. 2007
  8. ncbi Resolution of pansclerotic morphea after treatment with antithymocyte globulin
    Philip Song
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Nat Rev Rheumatol 5:513-6. 2009
  9. ncbi Immunotherapy of systemic sclerosis
    Rebecca Manno
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA
    Immunotherapy 2:863-78. 2010
  10. ncbi Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor
    Michael Maes
    IRCCS, Istituto, Fatebenefratelli, Brescia
    Schizophr Res 54:281-91. 2002

Collaborators

Detail Information

Publications11

  1. ncbi T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 58:1165-74. 2008
    ..The aim of this study was to investigate whether a polarized T cell phenotype in SSc is associated with lung disease or other clinical manifestations of SSc...
  2. ncbi Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
    ..94%). This small-volume ex vivo assay may prove to be a sensitive and specific tool to assess disease activity and to monitor response to therapy in patients with scleroderma...
  3. ncbi Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients
    Francesco Boin
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 60:2480-9. 2009
    ..This study was undertaken to investigate whether anti-beta2GPI and aCL are correlated with macrovascular disease, including ischemic digital loss and PAH, in SSc patients...
  4. ncbi Scleroderma-like fibrosing disorders
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:199-220; ix. 2008
    ..Rheumatologists must be able to promptly recognize them to provide valuable prognostic information and appropriate treatment options for affected patients...
  5. ncbi Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    Elizabeth N Le
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:1104-7. 2011
    ..Immunosuppressive therapy may potentially alter the natural disease course of scleroderma. There have been reports of using mycophenolate mofetil (MMF) for the treatment of scleroderma skin disease...
  6. ncbi Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
    Thomas Grader-Beck
    Correspondence to Thomas Grader Beck, Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Suite 4100, Mason Lord Center Tower, Baltimore, MD 21224, USA
    Ann Rheum Dis 70:2218-24. 2011
    ..Whether patients with SSc develop antibodies to carbohydrates is not known...
  7. ncbi Autoimmunity in systemic sclerosis: current concepts
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Bldg Center Tower, Suite 4100, Room 412, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 9:165-72. 2007
    ..Perturbed B-cell homeostasis has been reported in SSc. If confirmed in-vivo, these advances could lead to new disease-modifying therapeutic strategies directed at SSc-specific immune effector pathways...
  8. ncbi Resolution of pansclerotic morphea after treatment with antithymocyte globulin
    Philip Song
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Nat Rev Rheumatol 5:513-6. 2009
    ..He also reported difficulties with swallowing and a 20 kg weight loss...
  9. ncbi Immunotherapy of systemic sclerosis
    Rebecca Manno
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA
    Immunotherapy 2:863-78. 2010
    ..Clinical efficacy and safety of antifibrotic treatments (e.g., imatinib) await confirmation. Newer biological agents targeting key molecular or cellular effectors in scleroderma pathogenesis are now available for clinical testing...
  10. ncbi Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor
    Michael Maes
    IRCCS, Istituto, Fatebenefratelli, Brescia
    Schizophr Res 54:281-91. 2002
    ....
  11. ncbi Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia
    Luisella Bocchio Chiavetto
    Genetic Unit, IRCCS S Giovanni di Dio, Fatebenefratelli, Breschia, Italy
    Biol Psychiatry 51:480-4. 2002
    ..Three functional haplotypes of the gene (GCC, ACC, ATA) have been described, derived from different combinations of three "single nucleotide polymorphisms" and directly related to the expression levels of the protein...